In what scenario would the administration of Rho (D) immune globulin (RhoGAM) be indicated for a postpartum client?

The administration of Rho (D) immune globulin, commonly known as RhoGAM, is indicated in situations involving Rh incompatibility between a Rh-negative mother and an Rh-positive infant. The purpose of RhoGAM is to prevent the mother from developing antibodies against Rh-positive blood, which can occur during childbirth if the infant's blood enters the maternal circulation.

In the scenario where the mother is O negative and the infant is O positive, RhoGAM is warranted. This is because the mother’s Rh-negative status means she is at risk of forming antibodies against the Rh factor present in the baby's positive blood type. If the mother does produce these antibodies, future pregnancies with Rh-positive infants could lead to hemolytic disease of the newborn, a potentially serious condition.

This administration is typically effective when given within 72 hours postpartum, and it is critical for the well-being of both the mother and any future pregnancies. It’s important to monitor the mother's blood type and the infant's blood type as part of post-delivery care to ensure appropriate interventions like RhoGAM are provided when necessary.